Ideas

February 6, 2018

Published by admin_auro at February 6, 2018

Categories

Molecular therapy for body weight control, energy homeostasis and TIIDM: D-β-Hydroxybutyrate (D-βHB) increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 6/February/2018, 6.58 am

Introduction: What they say A study from the Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA shows that “Regulation of circadian behaviour […]

February 6, 2018

Published by admin_auro at February 6, 2018

Categories

Molecular therapy for TIIDM and obesity-associated metabolic deficits: D-3-hydroxybutyrate (D3HB) increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 6/February/2018, 6.45 am

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that […]

February 6, 2018

Published by admin_auro at February 6, 2018

Categories

Life-extension therapy: Lansoprazole, a drug used in the treatment of stomach and duodenal ulcers, inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span, 6/February/2017, 6.30 pm

What they say? A study from the Institute of Healthy Ageing, Centre for Diabetes and Endocrinology, Department of Medicine, University College London, London WC1E 6JJ, UK shows that “Ribosomal protein S6 […]

February 5, 2018

Published by admin_auro at February 5, 2018

Categories

Natural product-based therapy for TIIDM and obesity-associated metabolic deficits: D-3-Hydroxybutyrate (3DHB) increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 5/February/2018, 11.06 pm

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent […]